PHG

Business Context and Reporting Period

Company: Koninklijke Philips N.V. (Royal Philips)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: First Quarter 2025 (Ended March 31, 2025)
Filing Date: May 6, 2025

Philips reported Q1 2025 results characterized by a 2% decline in comparable sales, primarily driven by double-digit declines in China and a high comparison base in the Diagnosis & Treatment segment. Despite the sales decline, the company reported a return to profitability in income from operations, significantly aided by the absence of the massive litigation provision recorded in Q1 2024.

Key Financial Metrics

Liquidity: Cash and cash equivalents decreased from EUR 2,401 million to EUR 1,193 million. The Net Debt to Group Equity ratio shifted from 30:70 to 35:65.

Material Changes vs. Prior Period

• Profitability Reversal: Income from operations swung from a loss of EUR 824 million in Q1 2024 to a profit of EUR 154 million in Q1 2025. This is primarily due to the comparative impact of a EUR 982 million litigation provision recorded in Q1 2024 related to the Philips Respironics recall, which was not present in the current period.
• Sales Decline: Comparable sales fell 2%, driven by a double-digit decline in China across all segments. North America showed strong order intake growth, but sales were flat to slightly down due to currency and mix effects.
• Cash Flow Outflow: Free cash flow was a significant outflow of EUR 1,091 million, compared to EUR 336 million in the prior year. This was driven by a EUR 1,025 million cash payment for Philips Respironics recall-related medical monitoring and personal injury settlements in the US.
• Segment Performance:
  • Diagnosis & Treatment: Comparable sales down 4%; Adjusted EBITA margin improved to 9.5%.
  • Connected Care: Comparable sales flat; Adjusted EBITA margin declined to 3.5% due to unfavorable mix and cost phasing.
  • Personal Health: Comparable sales up 1%; Adjusted EBITA margin stable at 15.2%.

Guidance, Outlook, and Risks

Full Year 2025 Outlook Updates:

• Sales Growth: Unchanged at 1% to 3%.
• Adjusted EBITA Margin: Revised down to 10.8% - 11.3% (previously higher). This reflects an estimated net tariff impact of EUR 250-300 million after mitigations, representing a 100 bps reduction versus the previous outlook.
• Free Cash Flow: Expected to be slightly positive for the full year, following the EUR 1,025 million settlement payment in Q1.

Management Commentary: CEO Roy Jakobs highlighted continued order intake growth, particularly in the US and Personal Health. Management is focused on supply chain agility and cost actions to mitigate the financial impact of an uncertain macro environment and potential tariffs.

Risks and Contingencies:

• Tariffs: Outlook assumes current bilateral US-China and rest of world tariffs, including the resumption of paused US tariffs on July 9, 2025.
• Legal Proceedings: The outlook excludes ongoing Philips Respironics-related proceedings, including the investigation by the US Department of Justice.
• Macro Environment: Risks include geopolitical conflicts (Ukraine, Israel/Middle East) and global economic instability.

Investor Verification Checklist

• Settlement Impact: Verify the full extent of the EUR 1,025 million cash outflow and confirm no further immediate cash payments are expected for the Respironics settlements.
• Tariff Exposure: Assess the validity of the EUR 250-300 million tariff impact estimate and the effectiveness of mitigation strategies in the updated guidance.
• China Recovery: Monitor the double-digit sales decline in China for signs of stabilization or further deterioration in upcoming quarters.
• DOJ Investigation: Track developments in the US Department of Justice investigation regarding Philips Respironics, as this is excluded from current financial guidance.
• Order Intake Conversion: Evaluate whether the 2% growth in comparable order intake translates into sales growth in Q2 and beyond, given the current sales decline.